Literature DB >> 20004377

Pregnancy in women with polycystic ovary syndrome: the effect of different phenotypes and features on obstetric and neonatal outcomes.

Stefano Palomba1, Angela Falbo, Tiziana Russo, Achille Tolino, Francesco Orio, Fulvio Zullo.   

Abstract

OBJECTIVE: To test the hypothesis that the risk of adverse obstetric or neonatal outcomes varies according to different phenotypes of polycystic ovary syndrome (PCOS), and to evaluate the clinical impact of the main features of PCOS.
DESIGN: Prospective controlled clinical study.
SETTING: Academic Departments of Obstetrics and Gynecology, and of Endocrinology, Italy. PATIENT(S): Ninety-seven pregnant women with PCOS and 73 healthy pregnant subjects were recruited as cases and controls, respectively. INTERVENTION(S): Clinical, biochemical, and ultrasonographic evaluations. MAIN OUTCOME MEASURE(S): Obstetric and neonatal outcomes. RESULT(S): The relative risk (RR) for adverse obstetric or neonatal outcomes was increased (1.7, 95% confidence interval [CI] 1.12-2.96) in patients with PCOS and varied according to the PCOS phenotype (1.93, 95% CI 1.12-2.96; 2.23, 95% CI 1.21-3.15; 0.54, 95% CI 0.09-1.63, and 0.48, 95% CI 0.31-0.78 for full-blown, nonpolycystic ovaries [PCO], nonhyperandrogenic, and ovulatory phenotypes, respectively). The RRs were 1.57 (95% CI 0.85-2.52) and 0.48 (95% CI 0.31-0.78) for oligoanovulatory and ovulatory patients with PCOS, respectively. The risk for adverse obstetric or neonatal outcomes was affected significantly by ovarian dysfunction and biochemical hyperandrogenism, whereas no significant effect was detected for clinical hyperandrogenism and PCO. CONCLUSION(S): The increased risk for adverse obstetric and neonatal outcomes that was observed in patients with PCOS varies widely according to the different phenotypes and features of PCOS.
Copyright © 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 20004377     DOI: 10.1016/j.fertnstert.2009.10.043

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  31 in total

1.  Nesfatin-1 and other hormone alterations in polycystic ovary syndrome.

Authors:  Rulin Deniz; Bilgin Gurates; Suleyman Aydin; Husnu Celik; Ibrahim Sahin; Yakup Baykus; Zekiye Catak; Aziz Aksoy; Cihan Citil; Sami Gungor
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

2.  Maternal High-Fat Diet Consumption and Chronic Hyperandrogenemia Are Associated With Placental Dysfunction in Female Rhesus Macaques.

Authors:  Kelly Kuo; Victoria H J Roberts; Jessica Gaffney; Diana L Takahashi; Terry Morgan; Jamie O Lo; Richard L Stouffer; Antonio E Frias
Journal:  Endocrinology       Date:  2019-08-01       Impact factor: 4.736

Review 3.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

4.  Maternal polycystic ovarian syndrome and early offspring development.

Authors:  Griffith A Bell; Rajeshwari Sundaram; Sunni L Mumford; Hyojun Park; James Mills; Erin M Bell; Miranda Broadney; Edwina H Yeung
Journal:  Hum Reprod       Date:  2018-07-01       Impact factor: 6.918

Review 5.  A Narrative Review of Placental Contribution to Adverse Pregnancy Outcomes in Women With Polycystic Ovary Syndrome.

Authors:  Angela S Kelley; Yolanda R Smith; Vasantha Padmanabhan
Journal:  J Clin Endocrinol Metab       Date:  2019-11-01       Impact factor: 5.958

6.  Reproductive endocrinology: New guidelines for the diagnosis and treatment of PCOS.

Authors:  Francesco Orio; Stefano Palomba
Journal:  Nat Rev Endocrinol       Date:  2013-12-10       Impact factor: 43.330

7.  Changes in androgens and insulin sensitivity indexes throughout pregnancy in women with polycystic ovary syndrome (PCOS): relationships with adverse outcomes.

Authors:  Angela Falbo; Morena Rocca; Tiziana Russo; Antonietta D'Ettore; Achille Tolino; Fulvio Zullo; Francesco Orio; Stefano Palomba
Journal:  J Ovarian Res       Date:  2010-10-13       Impact factor: 4.234

8.  A comparison of IVF outcomes transferring a single ideal blastocyst in women with polycystic ovary syndrome and normal ovulatory controls.

Authors:  Naama Steiner; Senem Ates; Talya Shaulov; Guy Shrem; Alexander Volodarsky-Perel; S Yehuda Dahan; Samer Tannus; Weon-Young Son; Michael H Dahan
Journal:  Arch Gynecol Obstet       Date:  2020-07-15       Impact factor: 2.344

9.  Gestational Weight Gain in Women With Polycystic Ovary Syndrome: A Controlled Study.

Authors:  James Kent; William C Dodson; Allen Kunselman; Jaimey Pauli; Alicia Stone; Michael P Diamond; Christos Coutifaris; William D Schlaff; Ruben Alvero; Peter Casson; Gregory M Christman; R Mitchell Rosen; Karl R Hansen; Randall D Robinson; Valerie Baker; Rebecca Usadi; Nanette Santoro; Heping Zhang; Esther Eisenberg; Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

10.  DHEA-mediated inhibition of the pentose phosphate pathway alters oocyte lipid metabolism in mice.

Authors:  Patricia T Jimenez; Antonina I Frolova; Maggie M Chi; Natalia M Grindler; Alexandra R Willcockson; Kasey A Reynolds; Quihong Zhao; Kelle H Moley
Journal:  Endocrinology       Date:  2013-09-13       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.